A chitosan hexapeptide derivative and its preparation method and application
The nanostructure of chitosan hexapeptide derivatives enhances immune cell infiltration in tumors, solves the problems of recurrence and drug resistance in existing liver cancer treatments, significantly inhibits the growth of liver tumors in situ, and provides a new immunotherapy strategy.
Patent Information
- Application Number
- CN202310885514.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-07-19
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2043-07-19
AI Technical Summary
Existing treatment methods for liver cancer such as surgery, chemotherapy and radiofrequency ablation have problems with recurrence and drug resistance, and the response rate of immunotherapy such as PD-1 monoclonal antibody is limited, making it difficult to effectively inhibit liver tumor growth, especially for middle and late-stage patients. Not good.
Develop a chitosan hexapeptide derivative, which forms nanostructures by grafting Cys-Arg-Lys-Asp-Val-Tyr hexapeptide with chitosan at the amino site, extends the residence time at the absorption site and enhances Contact with the mucosa increases the number of infiltrated immune cells in the tumor, thereby inhibiting tumor growth.
Chitosan hexapeptide derivatives significantly inhibit tumor growth in the mouse model of liver orthotopic transplantation, increase the number of infiltrated immune cells in the tumor, and provide a new immunotherapy strategy with wide application prospects.
Smart Images

Figure CN116751319B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and specifically relates to a chitosan hexapeptide derivative and a preparation method and application thereof. Background Art
[0002] Cancer is a major disease that affects human health and life span, and has become one of the world's major public health issues. Among them, hepatocellular carcinoma (HCC) is one of the most common cancers in the world. For the treatment of liver cancer, surgery is the clinical first choice, but most patients have underlying liver disease or are already in the middle and late stages when diagnosed, and have few opportunities for surgical resection. Even if the operation is successful, liver cancer recurrence is an important factor that plagues the clinic. In addition, chemotherapy, radiofrequency ablation and other treatment methods have unsatisfactory clinical effects due to factors such as drug resistance and recurrence, and patients in the middle and late stages are unlikely to benefit.
[0003] Immunotherapy has brought new hope to liver cancer patients and has quickly become an important means of treating liver cancer in addition to surgery and chemotherapy. Liver cancer immunotherapy has also become a hot topic in clinical research on liver cancer. At present, immunotherapy for liver cancer is mainly based on immune checkpoint inhibitors, mainly PD-1 monoclonal antibodies. Although the prospects are promising, the response rate is limited and there is still much room for improvement. In order to benefit more liver cancer patients, the clinical treatment of liver cancer urgently needs the development of new immunotherapy strategies.
[0004] Peptides are an important type of drug. With the continuous progress of research and development, a wide variety of peptide drugs have been used in clinical practice. Thymopentin (Arg-Lys-Asp-Val-Tyr, abbreviated as RKDVY, TP5) is considered to be an effective fragment of thymopoietin (TP) with the same amino acid sequence and has a bidirectional immunomodulatory effect. In clinical practice, thymopentin for injection is mostly used for rheumatoid arthritis, chronic hepatitis, severe infection, and immune enhancement after tumor radiotherapy and chemotherapy. However, TP5 shows a very short half-life of about 30s in plasma, and repeated intramuscular or intravenous injections are inconvenient and painful for patients during the first 6 months of clinical treatment. Therefore, the development of a new thymic polypeptide delivery system has important clinical value. Summary of the invention
[0005] In view of this, the purpose of the present invention is to provide a chitosan hexapeptide derivative and a preparation method and application thereof. The chitosan hexapeptide derivative of the present invention can effectively resist liver tumors.
[0006] The present invention provides a chitosan hexapeptide derivative, which is obtained by grafting chitosan and Cys-Arg-Lys-Asp-Val-Tyr hexapeptide at any one or more amino sites of chitosan;
[0007] The chemical structural formula of the chitosan is shown in Formula II;
[0008]
[0009] Said n is a positive integer.
[0010] Preferably, the chemical structural formula of the chitosan hexapeptide derivative is as shown in Formula I;
[0011]
[0012] Preferably, when the concentration of the chitosan hexapeptide derivative is 0.1 mg / ml, the particle size of the chitosan hexapeptide derivative is less than 100 nm.
[0013] Preferably, the number average molecular weight of the chitosan is ≤3000Da.
[0014] The present invention also provides a method for preparing the chitosan hexapeptide derivatives described in the above scheme, comprising the following steps:
[0015] 1) mixing a succinimide 3-(2-pyridyldisulfide)-propionate solution and a chitosan solution to perform an activation reaction to obtain activated chitosan;
[0016] 2) The activated chitosan, Cys-Arg-Lys-Asp-Val-Tyr hexapeptide and tri(2-carboxyethyl)phosphine are mixed and cross-linked to obtain a chitosan hexapeptide derivative.
[0017] The present invention also provides the use of the chitosan hexapeptide derivatives described in the above scheme or the chitosan hexapeptide derivatives prepared by the preparation method in the preparation of drugs for anti-tumor and / or treatment of immune-related diseases.
[0018] Preferably, the tumor comprises a liver tumor.
[0019] Preferably, the anti-tumor effect includes increasing the number of infiltrating immune cells in the tumor.
[0020] The present invention also provides a drug for treating tumors and / or immune-related diseases, comprising the chitosan hexapeptide derivative described in the above scheme or the chitosan hexapeptide derivative prepared by the preparation method and pharmaceutically acceptable excipients.
[0021] Preferably, the dosage form of the drug includes an oral preparation or an injection.
[0022] The present invention provides a chitosan hexapeptide derivative, which can prolong its residence time at the absorption site, enhance its absorption by achieving close contact with the mucosa, increase the number of immune cells infiltrating the tumor, and enhance its anti-tumor effect. Therefore, the chitosan hexapeptide derivative of the present invention can increase the number of immune cells infiltrating the tumor and effectively inhibit the tumor. The chitosan hexapeptide derivative of the present invention can significantly inhibit the growth of tumors in a liver orthotopic transplantation mouse model, and has broad application prospects in the development of tumor immunotherapy agents. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 The synthetic route of the chitosan hexapeptide derivative of the present invention is as follows;
[0024] Figure 2 This is a representative transmission electron microscopy image of nanospheres formed by the chitosan hexapeptide derivative of the present invention in aqueous solution;
[0025] Figure 3 The infrared characteristic spectra of the chitosan hexapeptide derivative, chitosan and hexapeptide of the present invention;
[0026] Figure 4 This is a diagram showing the anti-tumor effect of the chitosan hexapeptide derivative of the present invention on a liver orthotopic tumor-bearing mouse model, which shows the liver tumor size and the statistical tumor size. DETAILED DESCRIPTION
[0027] The present invention provides a chitosan hexapeptide derivative, which is obtained by grafting chitosan and Cys-Arg-Lys-Asp-Val-Tyr hexapeptide at any one or more amino sites of chitosan;
[0028] The chemical structural formula of the chitosan is shown in Formula II;
[0029]
[0030] Said n is a positive integer.
[0031] In the present invention, the n is preferably 10; the number average molecular weight of the chitosan is preferably ≤3000Da.
[0032] In the present invention, the chitosan hexapeptide derivative is preferably obtained by grafting chitosan and Cys-Arg-Lys-Asp-Val-Tyr hexapeptide at any amino site of chitosan.
[0033] In the present invention, the chemical structural formula of the chitosan hexapeptide derivative is preferably as shown in Formula I;
[0034]
[0035] In the present invention, the chitosan hexapeptide derivative is preferably a nanostructure; when the concentration of the chitosan hexapeptide derivative is 0.1 mg / ml, the particle size of the chitosan hexapeptide derivative is within 100 nm.
[0036] In the present invention, CRKDVY is the hexapeptide cysteine-arginine-lysine-aspartic acid-valine-tyrosine, i.e. Cys-Arg-Lys-Asp-Val-Tyr (SEQ ID NO. 1).
[0037] The present invention also provides a method for preparing the chitosan hexapeptide derivatives described in the above scheme, comprising the following steps:
[0038] 1) mixing a succinimide 3-(2-pyridyldisulfide)-propionate solution (SPDP) and a chitosan solution to perform an activation reaction to obtain activated chitosan;
[0039] 2) The activated chitosan, Cys-Arg-Lys-Asp-Val-Tyr hexapeptide and tri(2-carboxyethyl)phosphine are mixed and cross-linked to obtain a chitosan hexapeptide derivative.
[0040] The invention firstly mixes a succinimide 3-(2-pyridyldisulfide)-propionate (SPDP) solution with a chitosan solution, and performs an activation reaction to obtain activated chitosan.
[0041] In the present invention, the solvent of the SPDP solution is dimethyl sulfoxide (DMSO); the concentration of SPDP in the SPDP solution is preferably 0.5-1 mg / μl, preferably 0.6 mg / μl. In the present invention, the solvent of the chitosan solution is preferably water; the mass ratio of SPDP to chitosan is preferably 60:(250-300), more preferably 60:273. In the present invention, the temperature of the activation reaction is preferably 20-30°C, more preferably 25°C; the time of the activation reaction is preferably 0.5-1.5h, more preferably 1h.
[0042] In the present invention, the SPDP reacts with the amino group of chitosan.
[0043] The present invention preferably further comprises filtering the reaction liquid after the activation reaction to collect the liquid component after the activation reaction; the filtration preferably comprises filtering by ultrafiltration centrifugation; the ultrafiltration centrifugation is preferably performed by an ultrafiltration tube with a specification of 3K; the rotation speed of the ultrafiltration centrifugation is preferably 5000 rpm; the time of the ultrafiltration centrifugation is preferably 20 to 30 minutes, more preferably 25 minutes.
[0044] After obtaining the activated chitosan, the present invention mixes the activated chitosan, Cys-Arg-Lys-Asp-Val-Tyr hexapeptide and tris(2-carboxyethyl)phosphine to carry out a cross-linking reaction to obtain a chitosan hexapeptide derivative.
[0045] In the present invention, the mixing of the activated chitosan, Cys-Arg-Lys-Asp-Val-Tyr hexapeptide and tris(2-carboxyethyl)phosphine (TCEP) preferably includes: first mixing the activated chitosan and TCEP to obtain a first mixed solution, during which the activated chitosan and TCEP undergo a cross-linking reaction; second mixing the first mixed solution and the Cys-Arg-Lys-Asp-Val-Tyr hexapeptide; the first mixing time is preferably 15 to 25 minutes, more preferably 20 minutes; the first mixing temperature is preferably 35 to 40°C, more preferably 37°C. In the present invention, the temperature of the cross-linking reaction is preferably 20 to 30°C, more preferably 25°C; the cross-linking reaction time is preferably 9 to 16 hours, more preferably 12 hours. After the cross-linking reaction, the present invention preferably further comprises centrifuging the reaction product of the cross-linking reaction, collecting the precipitate, washing the precipitate, and obtaining a product solution; the color of the product solution is light yellow; the speed of the centrifugation is preferably 5000 rpm; the time of the centrifugation is preferably 3 to 8 minutes, more preferably 5 minutes; the reagent used for the washing is preferably deionized water; the number of washings is preferably 3 times. After obtaining the product solution, the present invention preferably further comprises freeze-drying the product solution to obtain a powder; the color of the powder is yellow-brown.
[0046] The present invention also provides the use of the chitosan hexapeptide derivatives described in the above scheme or the chitosan hexapeptide derivatives prepared by the preparation method in the preparation of drugs for anti-tumor and / or treatment of immune-related diseases.
[0047] In the present invention, the tumor preferably includes a liver tumor.
[0048] In the present invention, the anti-tumor effect preferably includes increasing the number of infiltrating immune cells in tumors.
[0049] The present invention also provides a drug for treating tumors and / or immune-related diseases, comprising the chitosan hexapeptide derivative described in the above scheme or the chitosan hexapeptide derivative prepared by the preparation method and pharmaceutically acceptable excipients.
[0050] In the present invention, the dosage form of the drug preferably includes oral preparations or injections.
[0051] In the present invention, the chitosan hexapeptide derivative is the only active ingredient of the drug, or the chitosan hexapeptide derivative is used in combination with other anticancer drugs or drugs for treating immune-related diseases.
[0052] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention.
[0053] Example 1 Preparation of chitosan hexapeptide (Cys-Arg-Lys-Asp-Val-Tyr) derivatives
[0054] The synthetic route of chitosan hexapeptide derivatives can be found in Figure 1 .
[0055] Mix 60 mg of succinimidyl-3-2-thiopyridine propionate (SPDP) with 100 μL of dimethyl sulfoxide (DMSO) for use. Dissolve 273 mg of chitosan (chemical structure as shown in Formula II, n=10) in deionized water, mix the two solutions and stir them quickly, and let stand at room temperature for 1 hour. Balance a 3K ultrafiltration tube with deionized water for 10 minutes, centrifuge at 5000 rpm for 1 minute to remove the deionized water, add chitosan and SPDP / DMSO reaction solution, centrifuge at 5000 rpm for 25 minutes, repeat the centrifugation operation three times, and obtain an SPDP-activated chitosan solution. The obtained SPDP activated chitosan was reacted with trichloroethyl phosphate (tri(2-carboxyethyl)phosphine, TCEP) in a water bath at 37°C for 20 min, and then 100 mg of hexapeptide (Cys-Arg-Lys-Asp-Val-Tyr) dissolved in 500 μL of deionized water was added, reacted at room temperature for 12 h, centrifuged at 5000 rpm for 5 min, unreacted small molecules were washed away, and deionized water was added to wash the precipitate after centrifugation 3 times, and the precipitate was resuspended with deionized water to obtain a light yellow product solution, which was freeze-dried to obtain 357 mg of a yellow-brown powder.
[0056] Example 2 Transmission electron microscopy determination of chitosan hexapeptide derivatives
[0057] The derivative prepared in Example 1 was prepared into 1 mg / ml, 0.1 mg / ml, and 0.01 mg / ml aqueous solutions, and the solutions were dropped onto a copper mesh. After the solvent was evaporated, the nano-morphology was observed under a JEM-1230 transmission electron microscope. The measurement results showed that the derivative of the present invention formed regular nanospheres. Figure 2 This is a transmission electron microscope photo of a chitosan hexapeptide derivative at a concentration of 0.1 mg / ml, from which it can be seen that the nanostructure of the derivative of the present invention is mostly spheres with a diameter of about 100 nm. This type of nanostructure is very conducive to in vivo delivery.
[0058] Example 3 Determination of particle size distribution and surface zeta potential of chitosan hexapeptide derivatives in aqueous solution
[0059] The derivative prepared in Example 1 was prepared into 1 mg / ml, 0.1 mg / ml, and 0.01 mg / ml aqueous solutions, and the particle size was measured on a laser nanoparticle sizer (Zetasizer, NANO-S90) at 25°C. The measurement was continued for 2 days, and the particle size and zeta potential were recorded. The results are listed in Table 1. The data show that the nanoparticle size and zeta potential of the derivative of the present invention in aqueous solution are related to the concentration.
[0060] Table 1 Particle size (nm) and zeta potential (mV) of the derivatives of the present invention in aqueous solution for 2 days
[0061]
[0062] Example 4 Detection of characteristic peak changes of chitosan and chitosan hexapeptide derivatives by Fourier transform infrared spectroscopy
[0063] The characteristic spectra of dried chitosan, Cys-Arg-Lys-Asp-Val-Tyr hexapeptide and the chitosan hexapeptide (Cys-Arg-Lys-Asp-Val-Tyr) derivative prepared according to Example 1 were detected on a Nicoletis 5 infrared spectrometer. Figure 3 As shown in the chemical structure II, chitosan does not contain double bond structures such as amide bonds, while CRKDVY hexapeptide contains 5 amide bonds. Figure 3 Infrared spectrum shows 1639.06cm -1 The characteristic absorption peak at 1646.79 cm-1 can be observed in the infrared spectrum of chitosan-CRKDVY. -1 The amide bond absorption peak at 37° was detected, which proved that chitosan and CRKDVY were successfully connected.
[0064] Example 5 Inhibitory activity of chitosan hexapeptide derivatives on in situ liver tumor growth in mice
[0065] The experimental mice were randomly divided into 4 groups: control group, chitosan group, CRKDVY hexapeptide group, and chitosan hexapeptide derivative group, with 10 mice in each group.
[0066] Experimental method: The mice were anesthetized with sodium pentobarbital (50 mg / kg) and fixed in the supine position. A 1 cm incision was made in the midline of the abdomen below the xiphoid process of the mice. The mouse liver was carefully squeezed out. A 5 mm small incision was made in the right anterior lobe of the mouse liver with a needle. The small incision was deepened with ophthalmic forceps. The pre-prepared H22 tumor block (1.5 mm*1.5 mm) was inserted into the small incision. After pressing the small incision with an alcohol cotton ball to stop bleeding, the liver lobe was carefully slid into the abdominal cavity and the wound was sutured. Three days after tumor transplantation, the wound healing of the mice was observed, and the mice were weighed and randomly divided into 4 groups, with 10 mice in each group.
[0067] Administration: The drug dosage is 10 mg / kg body weight, and the administration method is intraperitoneal injection, which is administered every other day for 2 consecutive weeks.
[0068] After the administration, the mice were weighed and euthanized. The liver of the mice was taken to measure the tumor size and calculate the volume (the calculation formula is: (length × width 2 ) / 2).
[0069] The experimental data were statistically analyzed using t-test and variance analysis. ± SD). The results are shown in Table 2 and Figure 4 .
[0070] Table 2 Effects of chitosan hexapeptide derivatives on the size of in situ liver tumors in mice
[0071]
[0072] n=10, a means p<0.01 compared with the control group, b means p<0.01 compared with the chitosan group, c means p<0.01 compared with the hexapeptide group.
[0073] The experimental data results show that the chitosan hexapeptide derivatives of the present invention can significantly inhibit the growth of tumors in a liver orthotopic transplantation mouse model, while there is no significant difference between the administration of equal doses of chitosan and hexapeptide and the control group.
[0074] Example 6 Effects of chitosan hexapeptide derivatives on infiltrating immune cells in liver tumors of mice bearing liver orthotopic tumors.
[0075] Take the mouse tumor in Experimental Example 5, rinse with saline to remove floating blood, mince and add collagenase to digest for 30 minutes, terminate digestion with fetal bovine serum, filter with 40μm filter membrane, extract lymphocytes with mouse lymphocyte extract, lyse red blood cells and count and store. Antibodies labeled with metals, CD45\CD3\CD4\CD8\F4 / 80\CD16\NK P46 \The immune cells obtained by FOXP3 and other classification markers were detected and analyzed by flow cytometry mass spectrometry to determine the proportion of immune cell subsets in the CD45 positive cell population. The results are listed in Table 3.
[0076] The statistical analysis in this experiment was done using t-test and variance analysis. ±SDmg).
[0077] Table 3 Effects of chitosan hexapeptide derivatives on infiltrating immune cells in mouse liver in situ tumors
[0078]
[0079] n=10, a means p<0.01 compared with the control group, b means p<0.01 compared with the chitosan group, c means p<0.01 compared with the hexapeptide group.
[0080] The data showed that the proportions of T cells, NK cells and NKT cells in the chitosan hexapeptide derivative group were significantly increased, suggesting that the chitosan hexapeptide derivative of the present invention has the effect of inhibiting tumors by increasing the immune cells infiltrating into tumors.
[0081] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention rather than all the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. A chitosan hexapeptide derivative, characterized in that: It is obtained by grafting chitosan and Cys-Arg-Lys-Asp-Val-Tyr hexapeptide on any one or more amino sites of chitosan; The chemical structural formula of the chitosan is shown in Formula II; Said n is a positive integer; The chemical structural formula of the chitosan hexapeptide derivative is shown in Formula I; The number average molecular weight of the chitosan is ≤3000Da.
2. The chitosan hexapeptide derivative according to claim 1, characterized in that: When the concentration of the chitosan hexapeptide derivative is 0.1 mg / ml, the particle size of the chitosan hexapeptide derivative is less than 100 nm.
3. The method for preparing the chitosan hexapeptide derivative according to claim 1 or 2, characterized in that: The following steps are involved: 1) mixing a succinimide 3-(2-pyridyldisulfide)-propionate solution and a chitosan solution to perform an activation reaction to obtain activated chitosan; 2) The activated chitosan, Cys-Arg-Lys-Asp-Val-Tyr hexapeptide and tri(2-carboxyethyl)phosphine are mixed and cross-linked to obtain a chitosan hexapeptide derivative.
4. Use of the chitosan hexapeptide derivative according to claim 1 or 2 or the chitosan hexapeptide derivative prepared by the preparation method according to claim 3 in the preparation of drugs for anti-tumor and / or treatment of immune-related diseases.
5. The use according to claim 4, characterized in that: The tumor includes a liver tumor.
6. The use according to claim 4, characterized in that: The anti-tumor effect includes increasing the number of infiltrating immune cells in tumors.
7. A drug for treating tumors and / or immune-related diseases, characterized in that: The invention comprises the chitosan hexapeptide derivative according to claim 1 or 2 or the chitosan hexapeptide derivative prepared by the preparation method according to claim 3 and pharmaceutically acceptable auxiliary materials.
8. The drug according to claim 7, characterized in that The dosage form of the drug includes oral preparations or injections.
